(Q45275265)

11 December 2017

title

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma (English)

1 reference

11 December 2017

Ju-Yeon Cho

1

1 reference

11 December 2017

Yong-Han Paik

2

1 reference

11 December 2017

Ho Yeong Lim

3

1 reference

11 December 2017

Young Gon Kim

4

1 reference

11 December 2017

Hyo Keun Lim

5

1 reference

11 December 2017

Yang Won Min

6

1 reference

11 December 2017

Geum-Youn Gwak

7

1 reference

11 December 2017

Moon Seok Choi

8

1 reference

11 December 2017

Joon Hyeok Lee

9

1 reference

11 December 2017

Kwang Cheol Koh

10

1 reference

11 December 2017

Seung Woon Paik

11

1 reference

11 December 2017

Byung Chul Yoo

12

1 reference

11 December 2017

publication date

21 April 2013

1 reference

11 December 2017

1 reference

11 December 2017

volume

33

1 reference

11 December 2017

issue

6

1 reference

11 December 2017

page(s)

950-957

1 reference

11 December 2017

cites work

Global cancer statistics

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

21 January 2018

1 reference

Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience

21 January 2018

1 reference

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

21 January 2018

1 reference

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.

21 January 2018

1 reference

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

21 January 2018

1 reference

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

21 January 2018

1 reference

Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.

21 January 2018

1 reference

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits

21 January 2018

1 reference

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

21 January 2018

1 reference

Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis

21 January 2018

1 reference

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

21 January 2018

1 reference

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors

21 January 2018

1 reference

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

Sorafenib-associated hand-foot syndrome in Japanese patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12168

1 reference

11 December 2017

1 reference